Palvella Therapeutics (PVLA) Capital Expenditures Growth (3y) (2017 - 2023)
Palvella Therapeutics (PVLA) Capital Expenditures Growth (3y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -12.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -26.46% |
| Sep 30, 2023 | 27.69% |
| Jun 30, 2023 | -60.18% |
| Mar 31, 2023 | -70.80% |
| Dec 31, 2022 | -4.95% |
| Sep 30, 2022 | -84.24% |
| Jun 30, 2022 | -12.32% |
| Mar 31, 2022 | 47.59% |
| Dec 31, 2021 | -15.41% |
| Sep 30, 2021 | 2.50% |
| Jun 30, 2021 | -16.55% |
| Mar 31, 2021 | -59.26% |
| Dec 31, 2020 | -10.97% |
| Sep 30, 2020 | -69.93% |
| Jun 30, 2020 | 16.97% |
| Mar 31, 2020 | 120.81% |
| Dec 31, 2019 | 70.49% |
| Sep 30, 2019 | 5.41% |
| Jun 30, 2019 | 154.37% |
| Mar 31, 2019 | 21.23% |